Giredestrant combined with everolimus significantly extends progression-free survival in ER-positive, HER2-negative advanced breast cancer, especially in ESR1-mutated tumors, with a median of 10 months versus 5.5 months.
- 1 on Bluesky
New England Journal of Medicine
Massachusetts Medical Society · General Science & Medicine · ISSN 0028-4793, 1533-4406
- Impact (2-yr)
- 32.2
- h-index
- 1.5K
- Open access
- 13%
- Works
- 191.4K
- Papers this month
- 119
Rebuilt
Moved this week
Obinutuzumab significantly improves disease activity in adults with active systemic lupus erythematosus, achieving a 23.1 percentage point higher response rate than placebo at week 52.
- 25 cites
Once-weekly survodutide significantly reduces body weight by approximately 12-13% in adults with obesity without diabetes, outperforming placebo in a phase 3 trial.
- Open access
- 18 cites
A single dose of VERVE-102 achieved up to 88% reduction in PCSK9 and 62% decrease in LDL cholesterol in adults with hypercholesterolemia.
- Open access
- 32 cites
Teclistamab significantly improves progression-free and overall survival in relapsed or refractory multiple myeloma patients with 1-3 prior therapies, achieving 69.8% 18-month progression-free survival.
- 19 cites
Perioperative ADT plus apalutamide improves pathological response and metastasis-free survival in high-risk prostate cancer patients undergoing prostatectomy, with 8.9% achieving complete response.
- 26 cites
Finerenone slows kidney function decline and reduces cardiovascular and kidney events in adults with CKD without diabetes, with a significant eGFR preservation over 32 months.
- 22 cites
Daraxonrasib significantly improves overall survival and progression-free survival in previously treated metastatic pancreatic ductal adenocarcinoma, with median overall survival of 13.2 months versus 6.6 months for chemotherapy.
- 97 cites
Latest in NEJM
Newest first · last 60 days
Andes virus (ANDV) is the only orthohantavirus known to transmit between humans, posing unique challenges for disease control and management.
Obexelimab significantly delays disease flares and reduces glucocorticoid use in IgG4-related disease, with a hazard ratio of 0.44 and fewer flares compared to placebo.
- 2 cites
Giredestrant combined with everolimus significantly extends progression-free survival in ER-positive, HER2-negative advanced breast cancer, especially in ESR1-mutated tumors, with a median of 10 months versus 5.5 months.
- 1 on Bluesky
Atorvastatin reduces major cardiovascular events by 30% in adults aged 70 and older but does not extend disability-free survival over nearly six years.
Once-weekly oral islatravir-lenacapavir maintains HIV-1 suppression as effectively as daily B/F/TAF in a phase 3 trial with 607 adults.
Survodutide administered weekly leads to approximately 8-10% weight loss in adults with obesity and type 2 diabetes, outperforming placebo in a phase 3 trial.
Follow NEJM in the app
Browse JClub
Journals this month
- bioRxiv5569
- medRxiv1746
- Environ Res485
- PNAS463
- Sci Adv439
- JAMA255
- Cell Rep210
- BMJ205
- Nat Commun177
- Environ Pollution170
- Lancet149
- Science138
- NEJM119
- Applied & Environ Microbio116
- Curr Biol116
- J Exp Bot115
- mBio109
- Nature104
Moving areas, week to 3 Oct 2026
- Single-cell and spatial transcriptomics10
- Artificial Intelligence in Healthcare and Education8
- CAR-T cell therapy research7
- Neuroinflammation and Neurodegeneration Mechanisms6
- Lung Cancer Treatments and Mutations5
- Diabetes Treatment and Management4
- Pancreatic and Hepatic Oncology Research4
- Photosynthetic Processes and Mechanisms4
- Genomics and Chromatin Dynamics4
- Gut microbiota and health4